# Standard BioTools

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/standard-biotools

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.fluidigm.com
- Total disclosed funding: $110M
- Latest round: Series E (Nov 1, 2007)
- Investors on record: 15

## About

Standard BioTools Inc. specializes in life sciences tools, focusing on spatial biology and high-throughput genomics to enhance research capabilities across various scientific domains.Standard BioTools Inc. develops innovative tools for the life sciences sector. The company was founded in 1999 and is headquartered in San Francisco, US. Founded by William Roche, Standard BioTools has received funding through multiple rounds, with the most recent round being a PIPE, raising USD 250.00 mn from investors Casdin Capital and Viking Global Investors. The total amount raised by the company is USD 250.00 mn, and they have completed a total of 9 deals, with the latest deal occurring on February 15, 2011.Standard BioTools specializes in advanced life sciences tools, focusing on spatial biology and high-throughput genomics. Their core offerings include the CyTOF XT PRO, Hyperion XTi Imaging System, and the Biomark X9 System. These products enable multiplexed tissue imaging and genomic analysis, facilitating applications like immune profiling and biomarker discovery. The company primarily serves research institutions, pharmaceutical companies, and biotechnology firms in North America, Europe, and Asia, catering to diverse fields from immuno-oncology to sustainable agriculture.In 2022, Standard BioTools generated revenue of USD 72.45 mn, while reporting an EBITDA of USD -100.35 mn for the same year. The company earns revenue through the sales of its instruments and related reagents, engaging in direct sales to research labs and potential partnerships with pharmaceutical firms.Standard BioTools aims to leverage recent funding to support the development of new products and expand its market reach. The company is focusing on launching new products designed for enhanced genomic analysis, although specific release dates are not detailed. Additionally, they plan to target expansion into new geographic regions, which will be outlined in their strategic initiatives as they advance. The funding raised in the PIPE deal will assist in financing these growth efforts, paving the way for broader market penetration and innovation in their product lines.

## Funding rounds

- Series E, Nov 1, 2007, $34M — Alloy Ventures, EuclidSR Partners, Lilly Ventures, AllianceBernstein, Invus [DUP], Trilantic Capital Management L.P.
- Series E, Dec 31, 2006, $37M — Alloy Ventures, EuclidSR Partners, InterWest Partners, Versant Ventures, GE Capital Equity, Lilly Ventures, AllianceBernstein, SightLine Partners, Invus [DUP], SG Growth Capital, Lehman Brothers, Cross Creek
- Series E, Jun 21, 2006, $5M — Alloy Ventures, InterWest Partners, Versant Ventures, Lilly Ventures, AllianceBernstein, Invus [DUP], Trilantic Capital Management L.P.
- Series C, Nov 12, 2001, $34M — EuclidSR Partners, InterWest Partners, Versant Ventures, U.S. Bancorp, GE Capital Equity, Piper Sandler, Lehman Brothers

## Investors

- EuclidSR Partners (https://capitalatlas.ai/funds/euclidsr-partners) — Series C, Series E
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series C, Series E
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series C, Series E
- U.S. Bancorp — Series C
- GE Capital Equity — Series C, Series E
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series C
- Lehman Brothers (https://capitalatlas.ai/funds/lehman-brothers) — Series C, Series E
- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series E
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series E
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series E
- Invus [DUP] — Series E
- Trilantic Capital Management L.P. — Series E
- SightLine Partners — Series E
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series E
- Cross Creek (https://capitalatlas.ai/funds/cross-creek) — Series E